Mazdutide for Weight Management and Gout in Adults With Obesity

What this study is testing ClinicalTrials.gov NCT07824895 ↗

Description as written by the study sponsor.

This is a single-arm, open-label, pre-post controlled study to evaluate the effect of Mazdutide on the annualized flare rate (AFR) in adults with obesity and gout. The study will enroll 30 subjects aged 18 to 65 years with a Body Mass Index (BMI) ≥ 30.0 kg/m². Eligible participants must have a confirmed diagnosis of gout and a history of at least 2 gout flares in the past 6 months. The primary objective is to compare the AFR during the 52-week treatment period with the 12 months prior to treatment. All subjects will receive Mazdutide with a dose-escalation regimen, and their outcomes will be compared to their own baseline data.

Treatments tested

• Mazdutide also known as IBI362 Drug

  Mazdutide is a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It is administered via subcutaneous injection once weekly. The dosing regimen involves a titration strategy starting at 2 mg/week for the first 4 weeks, potentially increasing to 4 mg, 6 mg, or 9 mg based on tolerability and efficacy.